arrow
F

Fengshen Kuo

Memorial Sloan Kettering Cancer Center
H指数:33
被引数:9,848

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

INTEGRATIVE CLINICAL AND MOLECULAR CHARACTERIZATION OF METASTASIS AND RESISTANCE TO ANTIBODY-DRUG CONJUGATES IN SARCOMATOID VARIANT BLADDER CANCER

整合临床与分子特征研究肉瘤样变膀胱癌的转移及对抗体偶联药物的耐药性

2026-05-010
PRE
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer

尿路上皮癌对HER2靶向抗体药物偶联物的敏感性决定因素

2025-12-200
OAAI
Intratumoral early activated TCF1+CD4 Th cells drive effector CD8 T cell responses in a novel sarcomatoid RCC model through anti-CTLA4 therapy
2025-11-010
PRE
Hypoxia and immune suppression shapes therapeutic outcomes and metastases in clear cell renal cell carcinoma

缺氧和免疫抑制塑造了透明细胞肾细胞癌的治疗效果和转移。

2025-10-010
OAAI
Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma

分子异质性和免疫浸润驱动上尿路尿路上皮癌的临床结局

2025-03-011
OAAI
Tumor and blood B-cell abundance outperforms established immune checkpoint blockade response prediction signatures in head and neck cancer

肿瘤和血液B细胞丰度优于头颈部癌症中已建立的免疫检查点阻断反应预测特征。

2025-03-015
PRE
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
2023-08-2416
OA